Subscribe To
Fda clears lyell immunopharma' lyl132 trial for solid tumors
The FDA has cleared Lyell Immunopharma Inc's (NASDAQ: LYEL) Investigational New Drug (IND) application to initiate a Phase 1 trial for LYL132 in so...
January 24, 2022, 12:39 pm
Fda clears lyell immunopharma' lyl132 trial for solid tumors
The FDA has cleared Lyell Immunopharma Inc's (NASDAQ: LYEL) Investigational New Drug (IND) application to initiate a Phase 1 trial for LYL132 in so...
January 24, 2022, 12:39 pm
Merck's gefapixant for chronic cough slapped with fda complete response letter
The FDA has issued a Complete Response Letter (CRL) to Merck Co & Inc's (NYSE: MRK) gefapixant for refractory chronic cough (RCC) or unexplained c...
January 24, 2022, 7:14 am
Merck's gefapixant for chronic cough slapped with fda complete response letter
The FDA has issued a Complete Response Letter (CRL) to Merck Co & Inc's (NYSE: MRK) gefapixant for refractory chronic cough (RCC) or unexplained c...
January 24, 2022, 7:14 am
Merck's gefapixant for chronic cough slapped with fda complete response letter
The FDA has issued a Complete Response Letter (CRL) to Merck Co & Inc's (NYSE: MRK) gefapixant for refractory chronic cough (RCC) or unexplained c...
January 24, 2022, 7:14 am
Aslan pharma kickstarts mid-stage atopic dermatitis trial, data expected in 2023
ASLAN Pharmaceuticals Ltd (NASDAQ: ASLN) has screened the first patient in its Phase 2b dose-ranging study of eblasakimab (ASLAN004) in adults with...
January 21, 2022, 6:36 am
Aslan pharma kickstarts mid-stage atopic dermatitis trial, data expected in 2023
ASLAN Pharmaceuticals Ltd (NASDAQ: ASLN) has screened the first patient in its Phase 2b dose-ranging study of eblasakimab (ASLAN004) in adults with...
January 21, 2022, 6:36 am
Aslan pharma kickstarts mid-stage atopic dermatitis trial, data expected in 2023
ASLAN Pharmaceuticals Ltd (NASDAQ: ASLN) has screened the first patient in its Phase 2b dose-ranging study of eblasakimab (ASLAN004) in adults with...
January 21, 2022, 6:36 am
Celyad oncology announces january 2022 conference schedule
MONT-SAINT-GUIBERT, Belgium, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company fo...
December 22, 2021, 1:00 am
Celyad oncology announces january 2022 conference schedule
MONT-SAINT-GUIBERT, Belgium, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company fo...
December 22, 2021, 1:00 am
Celyad oncology announces january 2022 conference schedule
MONT-SAINT-GUIBERT, Belgium, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company fo...
December 22, 2021, 1:00 am
Cullinan oncology posts updated data for cln-081 in nsclc egfr exon 20 patients
Cullinan Oncology Inc (NASDAQ: CGEM) reported updated data from its ongoing Phase 1/2a trial of CLN-081 in non-small cell lung cancer (NSCLC) patie...
December 16, 2021, 1:04 pm
Cullinan oncology posts updated data for cln-081 in nsclc egfr exon 20 patients
Cullinan Oncology Inc (NASDAQ: CGEM) reported updated data from its ongoing Phase 1/2a trial of CLN-081 in non-small cell lung cancer (NSCLC) patie...
December 16, 2021, 1:04 pm
Cullinan oncology posts updated data for cln-081 in nsclc egfr exon 20 patients
Cullinan Oncology Inc (NASDAQ: CGEM) reported updated data from its ongoing Phase 1/2a trial of CLN-081 in non-small cell lung cancer (NSCLC) patie...
December 16, 2021, 1:04 pm
Should you buy chemocentryx stock as shares spike 70% on avacopan approval?
On Friday, ChemoCentryx Inc. (NASDAQ:CCXI) shares spiked nearly 70% after announcing the Food and Drug Administration (FDA) had approved avacopan for ...
October 8, 2021, 4:30 pm
Should you buy chemocentryx stock as shares spike 70% on avacopan approval?
On Friday, ChemoCentryx Inc. (NASDAQ:CCXI) shares spiked nearly 70% after announcing the Food and Drug Administration (FDA) had approved avacopan for ...
October 8, 2021, 4:30 pm
Should you buy chemocentryx stock as shares spike 70% on avacopan approval?
On Friday, ChemoCentryx Inc. (NASDAQ:CCXI) shares spiked nearly 70% after announcing the Food and Drug Administration (FDA) had approved avacopan for ...
October 8, 2021, 4:30 pm